CONMED (CNMD) Stock Forecast & Price Target

Conmed Corp has demonstrated robust growth in its key product segments, particularly with the BioBrace, which is set for a full release in the third quarter of 2025 following its FDA approval. The company's Foot & Ankle division has also shown double-digit growth despite supply constraints, indicating a positive trend in overcoming operational challenges. Furthermore, management's conservative revenue guidance reflects a commitment to achieving sustainable growth and improving top-line performance in the second half of the fiscal year.

Conmed Corp's stock outlook is negatively impacted by a year-to-date decline of approximately 27%, indicating persistent challenges as the company attempts to stabilize its performance. Moreover, the recent price target adjustment from $80 to $68 reflects ongoing pressure from capital weakness in the international market, primarily due to difficult year-over-year comparisons influenced by competitor product recalls and the introduction of new international distributors. This combination of stock pullback and operational hurdles suggests significant headwinds for the company's revenue growth and overall financial health moving forward.